Gene · 1294
Papers2,575
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,575
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Restoration of Hair Luster via Novel Biomarker COL7A1 by Minoxidil, Caffeine, and Biotin. | Curr Issues Mol Biol | 2025 | 40699867 | PubTator, text mining | PubMed |
| Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa. | J Dermatol | 2025 | 40667654 | PubTator, text mining | PubMed |
| Prevalence of kidney complications in a large cohort of patients with recessive dystrophic epidermolysis bullosa. | Br J Dermatol | 2025 | 40663638 | PubTator, text mining | PubMed |
| Complexities of care in a pediatric patient with epidermolysis bullosa acquisita and duchenne muscular dystrophy: a case report. | J Med Case Rep | 2025 | 40635014 | PubTator, text mining | PubMed |
| Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. | Lancet | 2025 | 40570869 | PubTator, text mining | PubMed |
| Clinical and Allelic Heterogeneity in a Small Cohort of Patients with Inherited Epidermolysis Bullosa. | Int J Mol Sci | 2025 | 40565224 | PubTator, text mining | PubMed |
| Induced Pluripotent (iPSC) and Mesenchymal (MSC) Stem Cells for In Vitro Disease Modeling and Regenerative Medicine. | Int J Mol Sci | 2025 | 40565081 | PubTator, text mining | PubMed |
| Integrative Machine Learning and Bioinformatics Approach for Identifying Key Biomarkers in Gallbladder Cancer Diagnosis and Progression. | IET Syst Biol | 2025 | 40527859 | PubTator, text mining | PubMed |
| Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinoma. | Br J Dermatol | 2025 | 40439508 | PubTator, text mining | PubMed |
| Safe and Efficacious Permanent Removal of Large COL7A1 Exons for Gene Reframing as a Reliable Therapeutic Strategy for Recessive Dystrophic Epidermolysis Bullosa. | Hum Gene Ther | 2025 | 40432605 | PubTator, text mining | PubMed |
| Multidimensional Evidence Chain of Nutritional Impact on Digestive System Tumors: Integration of Mendelian Randomization Causal Inference, NHANES Epidemiological Data, and Transcriptomic Analysis. | Nutr Cancer | 2025 | 40415396 | PubTator, text mining | PubMed |
| Rituximab for the Management of an Australian Cohort of Treatment Refractory Mucous Membrane Pemphigoid. | Australas J Dermatol | 2025 | 40377009 | PubTator, text mining | PubMed |
| Autoimmune bullous diseases: pathogenesis and clinical management. | Mol Biomed | 2025 | 40372624 | PubTator, text mining | PubMed |
| The Spectrum of Epidermolysis Bullosa in KwaZulu-Natal, South Africa. | Int J Dermatol | 2025 | 40369731 | PubTator, text mining | PubMed |
| Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets. | J Transl Med | 2025 | 40361150 | PubTator, text mining | PubMed |
| Collagen VII Is Associated with Airway Remodeling, Honeycombing, and Fibroblast Foci in Usual Interstitial Pneumonia/Idiopathic Pulmonary Fibrosis. | Am J Pathol | 2025 | 40311757 | PubTator, text mining | PubMed |
| Identification of Specific Biomarkers for Anaplastic Thyroid Carcinoma Through Spatial Transcriptomic and Immunohistochemical Profiling. | Endocr Pathol | 2025 | 40244468 | PubTator, text mining | PubMed |
| The utility of collagen VII topical gene therapy in the treatment of surgical defect after excision of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. | Br J Dermatol | 2025 | 40243007 | PubTator, text mining | PubMed |
| Dystrophic epidermolysis bullosa caused by novel frameshift mutation in the COL7A1 gene: A case report. | World J Clin Cases | 2025 | 40242224 | PubTator, text mining | PubMed |
| Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. | Am J Clin Dermatol | 2025 | 40220208 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1294/papers?page=6